AAD 2026Abstract 74215RCT
A Phase 1b Randomized, Double-Blind Multiple-Ascending Dose Study of NAV-240, an anti-OX40L/TNF-alpha Bispecific Antibody, in Healthy Volunteers
Daryani N, McClintock D, Pupim L, Chapas-Reed J, Mack T, Chung JK, Tagen M, Bonificio W, Thomas S, Grebe K, Daryani N
AAD Annual Meeting 2026Denver, 27–31 Mar 2026 · published in JAAD 6 Jul 2026
Topics: Cancer drugs
Abstract
The abstract’s text is on the JAAD website.
DOI 10.1016/j.jaad.2026.04.094 · Not in PubMed: details from Crossref